NCT02257918View on ClinicalTrials.gov

Randomized, Open-label Phase 2 Study of Oral AZD0914 in the Treatment of Gonorrhea

PHASE2CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

November 25, 2014

Primary Completion Date

December 30, 2015

Study Completion Date

December 30, 2015

Conditions
Gonorrhoea
Interventions
DRUG

AZD0914

AZD0914 is an antimicrobial amorphous nonsterile powder. Group 1 receive 2000 mg; Group 2 receive 3000 mg. The drug name is also known as ETX0914.

DRUG

Ceftriaxone

Ceftriaxone is a broad-spectrum cephalosporin antibiotic with a very long half-life and high penetrability to meninges, eyes and inner ears. A white to yellowish orange crystalline powder. Group 3 receives 500 mg reconstituted with 1 ml Lidocaine HCL 1%, intramuscularly.

Trial Locations (5)

70119

CrescentCare Health and Wellness Center, New Orleans

98104

Public Health STD Clinic, Seattle

35233-1502

Jefferson County Department of Health - STD Clinic, Birmingham

46202-5112

Indiana University - Bell Flower Clinic, Indianapolis

27701-3720

Durham County Health Department, Durham

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02257918 - Randomized, Open-label Phase 2 Study of Oral AZD0914 in the Treatment of Gonorrhea | Biotech Hunter | Biotech Hunter